Will allow firm to carry out live biologics and vaccine studies
Celerion, a specialist in early clinical research headquartered in Lincoln, Nebraska, has added a Containment Room at its UK facility in Belfast, Northern Ireland.
The expansion will allow the firm to develop programmes that require studies using biologics, as well as vaccines with primary and secondary containment.
The modular Containment Room comprises a negative pressure processing room, which houses a Biosafety Level (BSL-2) cabinet. Its addition further enhances the current GMP licensed site by enabling the firm to process live class 2 and class 3 biological products.
‘The addition of the Containment Room, coupled with our ability in the Belfast clinic to recruit large numbers of study participants, places Celerion in a strong position to conduct studies requiring biologics and vaccines,’ said Phil Bach, Celerion’s Vice President of Global Clinical Research.
This announcement builds on the recent addition of a Bronchoscopy Suite and expansion of Celerion’s services in the respiratory therapeutic area.
The Belfast facility also has extensive early stage clinical capabilities based on first-in-human experience with both NCEs and biologics, as well as bioequivalence, biosimilars, obesity, ophthalmic and gastro-intestinal studies.